State-of-the-Art Review: Molecular Markers in Thrombosis and Hemostasis

Abstract

Molecular markers for exploring the different stages of hemostasis activation are now available. These markers allow investigation of endothelial functions, blood cell activation, stimulation of coagulation pathways, involvement of the fibrinolytic system, and profiling of the coagulolytic-equilibrium that regulates hemostasis. Additionally, these markers find useful applications for monitoring therapies, following-up clinical states associated with high thrombotic risk, and validating new drugs and analyzing their mode of action. Furthermore, these markers may allow for recognition of the evolution of early disease in the clinically silent phase. Large scale epidemiological and longitudinal studies are required for establishing this latter approach. Up to now, only D. Dimer is used in routine clinical application for exclusion diagnosis of deep-veinous-thrombosis and pulmonary embolism. Other markers must prove their sensitivity for the early asymptomatic period and demonstrate their applicability throughout disease evolution. According to pathology and application, different markers may provide complementary information. Some markers, e.g., D. Dimer, soluble thrombomodulin, and modified AT-III (ATM), are used on standard citrated plasma samples. Modem and flexible technologies are now available for point-of-care testing (when required), quick and sensitive measurements in emergency conditions, and full automation when necessary. Lastly, factors that trigger hemostatic activation can now be evaluated and provide information on etiology. In this latter respect, autoimmunity may be important in thrombotic disease induction. Key Words: Hemostatic activation—Molecular markers— Thrombosis—Predictivity—Monitoring antithrombotic therapies.

Get full access to this article

View all access options for this article.

References

Risberg B. Pathophysiological mechanisms of thromboembolism. Acta Chir Scand 1989;(suppl)550:104—14.

McGinnis JM , Foege WH Actual causes of death in the United States. JAMA 1993;270:2207—12.

Fareed J. , Bick RL , Hoppensteadt DA Molecular markers of hemostatic activation: applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin Appl Thrombosis/Hemostasis 1995:1:87-102.

Bounameaux H. , de Moerloose P. , Perrier A. Plasma measurement of D. Dimer as diagnostic aid in suspected venous thromboembolism: an overview . Thromb Haemost 1994;71: 1-6.

Meade TW Hypercoagulability and ischaemic heart disease. Blood Rev 1987; 1:2-8.

Walters TK , Gorog DA , Wood Rfm. Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerosis process . J Vasc Res 1994;31:173-7.

Boisclair MD , Ireland H. , Lane DA Assessment of hypercoagulable states by measurement of activation fragments and peptides. Blood Rev 1990;4:25-40.

Chesterman CN Vascular endothelium, haemostasis and thrombosis . Blood Rev 1988;2:88-94.

Bick RL Disseminated intravascular coagulation: objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response. Clin Appl Thrombosis/Hemostasis 1995;1:3-23.

10.

Cooper DN The molecular genetics of familial venous thrombosis. Blood Rev 1991;5:55-70.

11.

Bachmann F. Plasminogen-plasmin enzyme system. In: Colman RW , Hirsh J , Marder VJ eds. Hemostasis and thrombosis: Basic principles and clinical practice. Philadelphia: Lippincott 1994, 1592-1622.

12.

Schafer AI Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994;344:1739-42.

13.

Zacharski LR , Wojtukiewicz MZ , Constantini V. Pathways of coagulation/fibrinolysis activation in malignancy. Sem Thromb Hemost 1992.18:104-16.

14.

Owen J. , Grossman BA , Palmer RH Hyperlipidemia and in vivo hemostatic system activation. Sem Thromb Hemost 1988; 14-241-45.

15.

Bick RL , Baker WF Antiphospholipid and thrombosis syndromes. Sem Thromb Hemost 1994;20:1-15.

16.

Bode W. , Stubbs MT Spatial structure of thrombin as a guide to its multiple sites of interactions . Semin Thromb Hemost 1993;19:321-33.

17.

Blann AD , Taberner DA A reliable marker of endothelial cell dysfunction: does it exist? Br J Haematol 1995;90:244-8.

18.

Hafner G. , Swars H. , Erbel R. , et al. Monitoring prothrombin fragment 1+2 during initiation of oral anticoagulant therapy after intraeoronary stenting. Ann Hematol 1992-,65:83-7.

19.

Lee AJ , Fowkes Fgr , Lowe Gdo. Determinants of fibrin D. Dimer in the Edinburgh artery study. Arterioscler Throm Vasc Bio. 1995;15:1094-7.

20.

Walenga JA , Fareed J. , Bick RL New anticoagulants for the cardiovascular patient. Clin Appl Thrombosis/Hemostasis 1995;1:24-30.

21.

Verstraete M. , Collen D. Thrombolytic therapy in the eighties . Blood 1986;67;1529-41 .

22.

Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis 1993;100:1-12.

23.

Tunstall-Pedoe H. , Kuulasmaa K. , Amouyel P. Myocardial infarction and coronary deaths in the world health organization: MONICA project. Circulation 1994;90:583-612.

24.

Amiral J. , Chambrette B. New technical approach for the thrombotic risk. Ann Biol Clin 1992;50:6-7.